N-Acetylaspartate in the CNS: From neurodiagnostics to neurobiology

Progress in Neurobiology

Volumn 81, Issue 2, 2007, Pages 89-131

  Moffett, John R ^a   Ross, Brian ^b,c   Arun, Peethambaran ^a   Madhavarao, Chikkathur N ^a   Namboodiri, Aryan M A ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

^c Rudi Schulte Research Institute   (United States)

Author keywords

Acetate; Acetyl coenzyme A; Aspartoacylase; Canavan disease; Dysmyelination; Energy metabolism; Lipid synthesis; Myelination; N acetyl l aspartic acid; NAA

Indexed keywords

2 OXOGLUTARIC ACID; ACETIC ACID; ACETYL COENZYME A; ASPARTIC ACID; ASPARTOACYLASE; DIPEPTIDE; FATTY ACID; GLUTAMIC ACID; MYELIN; N ACETYLASPARTIC ACID; N ACETYLASPARTYLGLUTAMIC ACID; NEUROPEPTIDE; STEROID;

ACETYLATION; ALZHEIMER DISEASE; BRAIN METABOLISM; BRAIN MITOCHONDRION; CANAVAN DISEASE; CELL VIABILITY; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR ACCIDENT; CITRIC ACID CYCLE; CYTOPLASM; ENERGY YIELD; EPILEPSY; FATALITY; FATTY ACID SYNTHESIS; GENE MUTATION; GLIA; HUMAN; LEUKODYSTROPHY; LIPID METABOLISM; LIPOGENESIS; METABOLITE; MITOCHONDRIAL ENERGY TRANSFER; MULTIPLE SCLEROSIS; MYELINATION; NERVE FIBER; NERVOUS SYSTEM DEVELOPMENT; NEUROBIOLOGY; NEUROTOXICITY; NITROGEN BALANCE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGODENDROGLIA; OSMOREGULATION; PERINATAL PERIOD; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STEROIDOGENESIS; TRAUMATIC BRAIN INJURY;

ANIMALS; ASPARTIC ACID; CANAVAN DISEASE; CENTRAL NERVOUS SYSTEM; ENERGY METABOLISM; HUMANS; LIPID METABOLISM; METABOLIC NETWORKS AND PATHWAYS;

EID: 33847141978     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2006.12.003     Document Type: Review

References (391)

1. Abbott C., and Bustillo J. What have we learned from proton magnetic resonance spectroscopy about schizophrenia? A critical update. Curr. Opin. Psychiatry 19 (2006) 135-139
2. Adachi M., Schneck L., Cara J., and Volk B.W. Spongy degeneration of the central nervous system (van Bogaert and Bertrand type; Canavan's disease). A review. Hum. Pathol. 4 (1973) 331-347
3. Akimitsu T., Kurisu K., Hanaya R., Iida K., Kiura Y., Arita K., Matsubayashi H., Ishihara K., Kitada K., Serikawa T., and Sasa M. Epileptic seizures induced by N-acetyl-l-aspartate in rats: in vivo and in vitro studies. Brain Res. 861 (2000) 143-150
4. Amstutz D.R., Coons S.W., Kerrigan J.F., Rekate H.L., and Heiserman J.E. Hypothalamic hamartomas: correlation of MR imaging and spectroscopic findings with tumor glial content. AJNR Am. J. Neuroradiol. 27 (2006) 794-798
5. Anderson K.J., Borja M.A., Cotman C.W., Moffett J.R., Namboodiri M.A., and Neale J.H. N-Acetylaspartylglutamate identified in the rat retinal ganglion cells and their projections in the brain. Brain Res. 411 (1987) 172-177
6. Ando S., Tanaka Y., Toyoda Y., and Kon K. Turnover of myelin lipids in aging brain. Neurochem. Res. 28 (2003) 5-13
7. Andreassen O.A., Dedeoglu A., Ferrante R.J., Jenkins B.G., Ferrante K.L., Thomas M., Friedlich A., Browne S.E., Schilling G., Borchelt D.R., Hersch S.M., Ross C.A., and Beal M.F. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol. Dis. 8 (2001) 479-491
8. Arnold D.L., Matthews P.M., Francis G., and Antel J. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. Magn. Reson. Med. 14 (1990) 154-159
9. Arnold D.L., Shoubridge E.A., Villemure J.G., and Feindel W. Proton and phosphorus magnetic resonance spectroscopy of human astrocytomas in vivo. Preliminary observations on tumor grading. NMR Biomed. 3 (1990) 184-189
10. Arun P., Madhavarao C.N., Hershfield J.R., Moffett J.R., and Namboodiri M.A. SH-SY5Y neuroblastoma cells: a model system for studying biosynthesis of NAAG. Neuroreport 15 (2004) 1167-1170
11. Arun P., Madhavarao C.N., Moffett J.R., and Namboodiri A.M. Regulation of N-acetylaspartate and N-acetylaspartylglutamate biosynthesis by protein kinase activators. J. Neurochem. 98 (2006) 2034-2042
12. Aubert A., Costalat R., Magistretti P.J., and Pellerin L. Brain lactate kinetics: modeling evidence for neuronal lactate uptake upon activation. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 16448-16453
13. Bai X., Chen X., Feng Z., Hou K., Zhang P., Fu B., and Shi S. Identification of basolateral membrane targeting signal of human sodium-dependent dicarboxylate transporter 3. J. Cell. Physiol. 206 (2006) 821-830
14. Bammer R., Skare S., Newbould R., Liu C., Thijs V., Ropele S., Clayton D.B., Krueger G., Moseley M.E., and Glover G.H. Foundations of advanced magnetic resonance imaging. NeuroRx 2 (2005) 167-196
15. Barany M., Spigos D.G., Mok E., Venkatasubramanian P.N., Wilbur A.C., and Langer B.G. High resolution proton magnetic resonance spectroscopy of human brain and liver. Magn. Reson. Imaging 5 (1987) 393-398
16. Barker P.B., Bonekamp D., Riedy G., and Smith M. Quantitation of NAA in the brain by magnetic resonance spectroscopy. In: Moffett J.R., Tieman S.B., Weinberger D.R., Coyle J.T., and Namboodiri M.A. (Eds). N-Acetylaspartate: A Unique Neuronal Molecule in the Central Nervous System (2006), Springer Science, New York, NY 183-197
17. Barker P.B., and Gillard J.H. MR Spectroscopy in stroke. In: Gillard J., Waldman A., and Barker P.B. (Eds). Clinical MR Neuroimaging: Diffusion, Perfusion and Spectroscopy (2005), Cambridge University Press, New York, NY 168-181
18. Barkovich A.J., Baranski K., Vigneron D., Partridge J.C., Hallam D.K., Hajnal B.L., and Ferriero D.M. Proton MR spectroscopy for the evaluation of brain injury in asphyxiated, term neonates. AJNR Am. J. Neuroradiol. 20 (1999) 1399-1405
19. Bartalini G., Margollicci M., Balestri P., Farnetani M.A., Cioni M., and Fois A. Biochemical diagnosis of Canavan disease. Childs Nerv. Syst. 8 (1992) 468-470
20. Baslow M.H. A review of phylogenetic and metabolic relationships between the acylamino acids, N-acetyl-l-aspartic acid and N-acetyl-l-histidine, in the vertebrate nervous system. J. Neurochem. 68 (1997) 1335-1344
21. Baslow M.H. Function of the N-acetyl-l-histidine system in the vertebrate eye. Evidence in support of a role as a molecular water pump. J. Mol. Neurosci. 10 (1998) 193-208
22. Baslow M.H. The existence of molecular water pumps in the nervous system: a review of the evidence. Neurochem. Int. 34 (1999) 77-90
23. Baslow M.H. Canavan's spongiform leukodystrophy: a clinical anatomy of a genetic metabolic CNS disease. J. Mol. Neurosci. 15 (2000) 61-69
24. Baslow M.H. Functions of N-acetyl-l-aspartate and N-acetyl-l-aspartylglutamate in the vertebrate brain: role in glial cell-specific signaling. Neurochem. J. 75 (2000) 453-459
25. Baslow M.H. Evidence supporting a role for N-acetyl-l-aspartate as a molecular water pump in myelinated neurons in the central nervous system. An analytical review. Neurochem. Int. 40 (2002) 295-300
26. Baslow M.H. Brain N-acetylaspartate as a molecular water pump and its role in the etiology of Canavan disease: a mechanistic explanation. J. Mol. Neurosci. 21 (2003) 185-190
27. Baslow M.H. N-Acetylaspartate in the vertebrate brain: metabolism and function. Neurochem. Res. 28 (2003) 941-953
28. Baslow M.H., and Guilfoyle D.N. Effect of N-acetylaspartic acid on the diffusion coefficient of water: a proton magnetic resonance phantom method for measurement of osmolyte-obligated water. Anal. Biochem. 311 (2002) 133-138
29. Baslow M.H., and Guilfoyle D.N. Functions of N-acetylaspartate and N-acetylaspartylglutamate in brain: evidence of a role in maintenance of higher brain integrative activities of information processing and cognition. In: Moffett J.R., Tieman S.B., Weinberger D.R., Coyle J.T., and Namboodiri M.A. (Eds). N-Acetylaspartate: A Unique Neuronal Molecule in the Central Nervous System (2006), Springer Science, New York, NY 95-112
30. Baslow M.H., Kitada K., Suckow R.F., Hungund B.L., and Serikawa T. The effects of lithium chloride and other substances on levels of brain N-acetyl-l-aspartic acid in Canavan disease-like rats. Neurochem. Res. 27 (2002) 403-406
31. Baslow M.H., Suckow R.F., and Hungund B.L. Effects of ethanol and of alcohol dehydrogenase inhibitors on the reduction of N-acetylaspartate levels of brain in mice in vivo: a search for substances that may have therapeutic value in the treatment of Canavan disease. J. Inherit. Metab. Dis. 23 (2000) 684-692
32. Baslow M.H., Suckow R.F., Sapirstein V., and Hungund B.L. Expression of aspartoacylase activity in cultured rat macroglial cells is limited to oligodendrocytes. J. Mol. Neurosci. 13 (1999) 47-53
33. Baslow M.H., and Yamada S. Identification of N-acetylaspartate in the lens of the vertebrate eye: a new model for the investigation of the function of N-acetylated amino acids in vertebrates. Exp. Eye Res. 64 (1997) 283-286
34. Bates T.E., Strangward M., Keelan J., Davey G.P., Munro P.M., and Clark J.B. Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo. Neuroreport 7 (1996) 1397-1400
35. Bauer D.E., Hatzivassiliou G., Zhao F., Andreadis C., and Thompson C.B. ATP citrate lyase is an important component of cell growth and transformation. Oncogene 24 (2005) 6314-6322
36. Begum L., Jalil M.A., Kobayashi K., Iijima M., Li M.X., Yasuda T., Horiuchi M., Del A.A., Satrustegui J., and Saheki T. Expression of three mitochondrial solute carriers, citrin, aralar1 and ornithine transporter, in relation to urea cycle in mice. Biochim. Biophys. Acta 1574 (2002) 283-292
37. Behar K.L., Boucher R., Fritch W., and Manuelidis L. Changes in N-acetylaspartate and myo-inositol detected in the cerebral cortex of hamsters with Creutzfeldt-Jakob disease. Magn. Reson. Imaging 16 (1998) 963-968
38. Beigneux A.P., Kosinski C., Gavino B., Horton J.D., Skarnes W.C., and Young S.G. ATP-citrate lyase deficiency in the mouse. J. Biol. Chem. 279 (2004) 9557-9564
39. Benuck M., and D'Adamo Jr. A.F. Acetyl transport mechanisms. Metabolism of N-acetyl-l-aspartic acid in the non-nervous tissues of the rat. Biochim. Biophys. Acta 152 (1968) 611-618
40. Berger U.V., Luthi-Carter R., Passani L.A., Elkabes S., Black I., Konradi C., and Coyle J.T. Glutamate carboxypeptidase II is expressed by astrocytes in the adult rat nervous system. J. Comp. Neurol. 415 (1999) 52-64
41. Bertolino A., Breier A., Callicott J.H., Adler C., Mattay V.S., Shapiro M., Frank J.A., Pickar D., and Weinberger D.R. The relationship between dorsolateral prefrontal neuronal N-acetylaspartate and evoked release of striatal dopamine in schizophrenia. Neuropsychopharmacology 22 (2000) 125-132
42. Bertolino A., Nawroz S., Mattay V.S., Barnett A.S., Duyn J.H., Moonen C.T., Frank J.A., Tedeschi G., and Weinberger D.R. Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. Am. J. Psychiatry 153 (1996) 1554-1563
43. Bertolino A., and Weinberger D.R. Proton magnetic resonance spectroscopy in schizophrenia. Eur. J. Radiol. 30 (1999) 132-141
44. Bhakoo K.K., Craig T.J., and Styles P. Developmental and regional distribution of aspartoacylase in rat brain tissue. J. Neurochem. 79 (2001) 211-220
45. Bhakoo K.K., and Pearce D. In vitro expression of N-acetyl aspartate by oligodendrocytes: implications for proton magnetic resonance spectroscopy signal in vivo. J. Neurochem. 74 (2000) 254-262
46. Birnbaum S.M. Amino acid acylases I and II from hog kidney. Methods Enzymol. 2 (1955) 115-119
47. Birnbaum S.M., Levintow L., Kingsley R.B., and Greenstein J.P. Specificity of amino acid acylases. J. Biol. Chem. 194 (1952) 455-470
48. Bjartmar C., Battistuta J., Terada N., Dupree E., and Trapp B.D. N-Acetylaspartate is an axon-specific marker of mature white matter in vivo: a biochemical and immunohistochemical study on the rat optic nerve. Ann. Neurol. 51 (2002) 51-58
49. Blakely R.D., Robinson M.B., Thompson R.C., and Coyle J.T. Hydrolysis of the brain dipeptide N-acetyl-l-aspartyl-l-glutamate: subcellular and regional distribution, ontogeny, and the effect of lesions on N-acetylated-alpha-linked acidic dipeptidase activity. J. Neurochem. 50 (1988) 1200-1209
50. Bluml S. In vivo quantitation of cerebral metabolite concentrations using natural abundance 13C MRS at 1.5 T. J. Magn. Reson. 136 (1999) 219-225
51. Bluml S., Moreno-Torres A., Shic F., Nguy C.H., and Ross B.D. Tricarboxylic acid cycle of glia in the in vivo human brain. NMR Biomed. 15 (2002) 1-5
52. Boltshauser E., Schmitt B., Wevers R.A., Engelke U., Burlina A.B., and Burlina A.P. Follow-up of a child with hypoacetylaspartia. Neuropediatrics 35 (2004) 255-258
53. Bonnet M., Ducournau D., Lumbroso P., and Serpin G. N-acetyl-aspartylglutamic acid eye drops in allergic-type conjuctivitis. Double-blind comparative clinical study. J. Fr. Ophtalmol. 8 (1985) 573-578
54. Bothwell J.H., Rae C., Dixon R.M., Styles P., and Bhakoo K.K. Hypo-osmotic swelling-activated release of organic osmolytes in brain slices: implications for brain oedema in vivo. J. Neurochem. 77 (2001) 1632-1640
55. Bradford H.F., and Thomas A.J. Metabolism of glucose and glutamate by synaptosomes from mammalian cerebral cortex. J. Neurochem. 16 (1969) 1495-1504
56. Briellmann R.S., Wellard R.M., and Jackson G.D. Seizure-associated abnormalities in epilepsy: evidence from MR imaging. Epilepsia 46 (2005) 760-766
57. Brooks W.M., Friedman S.D., and Gasparovic C. Magnetic resonance spectroscopy in traumatic brain injury. J. Head Trauma Rehabil. 16 (2001) 149-164
58. Brown A.M., and Lemke G. Multiple regulatory elements control transcription of the peripheral myelin protein zero gene. J. Biol. Chem. 272 (1997) 28939-28947
59. Bruhn H., Frahm J., Gyngell M.L., Merboldt K.D., Hanicke W., Sauter R., and Hamburger C. Noninvasive differentiation of tumors with use of localized H-1 MR spectroscopy in vivo: initial experience in patients with cerebral tumors [see comments]. Radiology 172 (1989) 541-548
60. Bruhn H., Frahm J., Gyngell M.L., Merboldt K.D., Hanicke W., and Sauter R. Cerebral metabolism in man after acute stroke: new observations using localized proton NMR spectroscopy. Magn. Reson. Med. 9 (1989) 126-131
61. Bruhn H., Frahm J., Merboldt K.D., Hanicke W., Hanefeld F., Christen H.J., Kruse B., and Bauer H.J. Multiple sclerosis in children: cerebral metabolic alterations monitored by localized proton magnetic resonance spectroscopy in vivo. Ann. Neurol. 32 (1992) 140-150
62. Brunengraber H., and Roe C.R. Anaplerotic molecules: current and future. J. Inherit. Metab. Dis. 29 (2006) 327-331
63. Buniatian H.C., Hovhannissian V.S., and Aprikian G.V. The participation of N-acetyl-l-aspartic acid in brain metabolism. J. Neurochem. 12 (1965) 695-703
64. Burgal M., Jorda A., and Grisolia S. Effects of N-acetyl aspartate, aspartate, and glutamate on cAMP and cGMP levels in developing rat cerebral cortex. J. Neurochem. 38 (1982) 1498-1500
65. Burlina A.P., Corazza A., Ferrari V., Erhard P., Kunnecke B., Seelig J., and Burlina A.B. Detection of increased urinary N-acetylaspartylglutamate in Canavan disease [letter]. Eur. J. Pediatr. 153 (1994) 538-539
66. Burlina A.P., Ferrari V., Burlina A.B., Ermani M., Boespflug-Tanguy O., and Bertini E. N-Acetylaspartylglutamate (NAAG) in Pelizaeus-Merzbacher disease. In: Moffett J.R., Tieman S.B., Weinberger D.R., Coyle J.T., and Namboodiri M.A. (Eds). N-Acetylaspartate: A Unique Neuronal Molecule in the Central Nervous System (2006), Springer Science, New York, NY 353-359
67. Burlina A.P., Ferrari V., Facci L., Skaper S.D., and Burlina A.B. Mast cells contain large quantities of secretagogue-sensitive N-acetylaspartate. J. Neurochem. 69 (1997) 1314-1317
68. Burlina A.P., Schmitt B., Engelke U., Wevers R.A., Burlina A.B., and Boltshauser E. Hypoacetylaspartia: clinical and biochemical follow-up of a patient. Adv. Exp. Med. Biol. 576 (2006) 283-287
69. Burri R., Bigler P., Straehl P., Posse S., Colombo J.P., and Herschkowitz N. Brain development: 1H magnetic resonance spectroscopy of rat brain extracts compared with chromatographic methods. Neurochem. Res. 15 (1990) 1009-1016
70. Burri R., Steffen C., and Herschkowitz N. N-Acetyl-l-aspartate is a major source of acetyl groups for lipid synthesis during rat brain development. Dev. Neurosci. 13 (1991) 403-412
71. Bustillo J., Barrow R., Paz R., Tang J., Seraji-Bozorgzad N., Moore G.J., Bolognani F., Lauriello J., Perrone-Bizzozero N., and Galloway M.P. Long-term treatment of rats with haloperidol: lack of an effect on brain N-acetyl aspartate levels. Neuropsychopharmacology 31 4 (2005) 751-756
72. Bustillo J., Wolff C., Gutierrez A., Dettmer T.S., Cooper T.B., Allan A., Lauriello J., and Valenzuela C.F. Treatment of rats with antipsychotic drugs: lack of an effect on brain N-acetyl aspartate levels. Schizophr. Res. 66 (2004) 31-39
73. Callicott J.H., Bertolino A., Egan M.F., Mattay V.S., Langheim F.J., and Weinberger D.R. Selective relationship between prefrontal N-acetylaspartate measures and negative symptoms in schizophrenia. Am. J. Psychiatry 157 (2000) 1646-1651
74. Callicott J.H., Bertolino A., Mattay V.S., Langheim F.J., Duyn J., Coppola R., Goldberg T.E., and Weinberger D.R. Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb. Cortex 10 (2000) 1078-1092
75. Canavan M.M. Schilder's encephalitis perioxalis diffusa. Neurology 15 (1931) 299-308
76. Cangro C.B., Namboodiri M.A., Sklar L.A., Corigliano-Murphy A., and Neale J.H. Immunohistochemistry and biosynthesis of N-acetylaspartylglutamate in spinal sensory ganglia. J. Neurochem. 49 (1987) 1579-1588
77. Cappellini M., Rapisardi G., Cioni M.L., and Fonda C. Acute hypoxic encephalopathy in the full-term newborn: correlation between Magnetic Resonance Spectroscopy and neurological evaluation at short and long term. Radiol. Med. (Torino) 104 (2002) 332-340
78. Caramanos Z., Narayanan S., and Arnold D.L. 1H-MRS quantification of tNA and tCr in patients with multiple sclerosis: a meta-analytic review. Brain 128 (2005) 2483-2506
79. Cartmell J., and Schoepp D.D. Regulation of neurotransmitter release by metabotropic glutamate receptors. J. Neurochem. 75 (2000) 889-907
80. Cassidy M., and Neale J.H. Localization and transport of N-acetylaspartylglutamate in cells of whole murine brain in primary culture. J. Neurochem. 60 (1993) 1631-1638
81. Cassidy M., and Neale J.H. N-Acetylaspartylglutamate catabolism is achieved by an enzyme on the cell surface of neurons and glia. Neuropeptides 24 (1993) 271-278
82. Chakraborty G., Mekala P., Yahya D., Wu G., and Ledeen R.W. Intraneuronal N-acetylaspartate supplies acetyl groups for myelin lipid synthesis: evidence for myelin-associated aspartoacylase. J. Neurochem. 78 (2001) 736-745
83. Chang L., Ernst T., Tornatore C., Aronow H., Melchor R., Walot I., Singer E., and Cornford M. Metabolite abnormalities in progressive multifocal leukoencephalopathy by proton magnetic resonance spectroscopy. Neurology 48 (1997) 836-845
84. Chevance L.G., and Etievant M. A peptide (a magnesium salt of N-acetyl(alpha, beta)-aspartyl-glutamic acid). Demonstration of the protection against local cellular destruction induced by in situ complement activation. J. Pharmacol. 17 (1986) 676-685
85. Chih C.P., and Roberts Jr. E.L. Energy substrates for neurons during neural activity: a critical review of the astrocyte-neuron lactate shuttle hypothesis. J. Cereb. Blood Flow Metab. 23 (2003) 1263-1281
86. Chinn R.J., Wilkinson I.D., Hall-Craggs M.A., Paley M.N., Miller R.F., Kendall B.E., Newman S.P., and Harrison M.J. Toxoplasmosis and primary central nervous system lymphoma in HIV infection: diagnosis with MR spectroscopy. Radiology 197 (1995) 649-654
87. Choi I.Y., and Gruetter R. In vivo 13C NMR assessment of brain glycogen concentration and turnover in the awake rat. Neurochem. Int. 43 (2003) 317-322
88. Choi I.Y., and Gruetter R. Dynamic or inert metabolism? Turnover of N-acetyl aspartate and glutathione from d-[1-13C]glucose in the rat brain in vivo. J. Neurochem. 91 (2004) 778-787
89. Chuang M.T., Lin W.C., Tsai H.Y., Liu G.C., Hu S.W., and Chiang I.C. 3-T proton magnetic resonance spectroscopy of central neurocytoma: 3 case reports and review of the literature. J. Comput. Assist. Tomogr. 29 (2005) 683-688
90. Clark J.B. N-Acetyl aspartate: a marker for neuronal loss or mitochondrial dysfunction. Dev. Neurosci. 20 (1998) 271-276
91. Clark J.F., Doepke A., Filosa J.A., Wardle R.L., Lu A., Meeker T.J., and Pyne-Geithman G.J. N-Acetylaspartate as a reservoir for glutamate. Med. Hypotheses 67 3 (2006) 506-512
92. Clarke D.D., Greenfield S., Dicker E., Tirri L.J., and Ronan E.J. A relationship of N-acetylaspartate biosynthesis to neuronal protein synthesis. J. Neurochem. 24 (1975) 479-485
93. Coetzee T., Dupree J.L., and Popko B. Demyelination and altered expression of myelin-associated glycoprotein isoforms in the central nervous system of galactolipid-deficient mice. J. Neurosci. Res. 54 (1998) 613-622
94. Coetzee T., Suzuki K., and Popko B. New perspectives on the function of myelin galactolipids. Trends Neurosci. 21 (1998) 126-130
95. Coon A.L., rias-Mendoza F., Colby G.P., Cruz-Lobo J., Mocco J., Mack W.J., Komotar R.J., Brown T.R., and Connolly Jr. E.S. Correlation of cerebral metabolites with functional outcome in experimental primate stroke using in vivo 1H-magnetic resonance spectroscopy. AJNR Am. J. Neuroradiol. 27 (2006) 1053-1058
96. Cooper A.J. Role of glutamine in cerebral nitrogen metabolism and ammonia neurotoxicity. Ment. Retard. Dev. Disabil. Res. Rev. 7 (2001) 280-286
97. Cooper A.J., McDonald J.M., Gelbard A.S., Gledhill R.F., and Duffy T.E. The metabolic fate of 13N-labeled ammonia in rat brain. J. Biol. Chem. 254 (1979) 4982-4992
98. Criste G.A., and Trapp B.D. N-Acetyl-l-aspartate in multiple sclerosis. In: Moffett J.R., Tieman S.B., Weinberger D.R., Coyle J.T., and Namboodiri M.A. (Eds). N-Acetylaspartate: A Unique Neuronal Molecule in the Central Nervous System (2006), Springer Science, New York, NY 199-214
99. D'Adamo Jr. A.F., Gidez L.I., and Yatsu F.M. Acetyl transport mechanisms. Involvement of N-acetyl aspartic acid in de novo fatty acid biosynthesis in the developing rat brain. Exp. Brain Res. 5 (1968) 267-273
100. D'Adamo Jr. A.F., Peisach J., Manner G., and Weiler C.T. N-Acetyl-aspartate amidohydrolase: purification and properties. J. Neurochem. 28 (1977) 739-744
101. D'Adamo Jr. A.F., Smith J.C., and Woiler C. The occurrence of N-acetylaspartate amidohydrolase (aminoacylase II) in the developing rat. J. Neurochem. 20 (1973) 1275-1278
102. D'Adamo Jr. A.F., and Yatsu F.M. Acetate metabolism in the nervous system. N-Acetyl-l-aspartic acid and the biosynthesis of brain lipids. J. Neurochem. 13 (1966) 961-965
103. Danielsen E.R., and Ross B. Magnetic Resonance Spectroscopy Diagnosis of Neurological Diseases (1999), Marcel Dekker, New York
104. Dautry C., Vaufrey F., Brouillet E., Bizat N., Henry P.G., Conde F., Bloch G., and Hantraye P. Early N-acetylaspartate depletion is a marker of neuronal dysfunction in rats and primates chronically treated with the mitochondrial toxin 3-nitropropionic acid. J. Cereb. Blood Flow Metab. 20 (2000) 789-799
105. Davie C.A., Hawkins C.P., Barker G.J., Brennan A., Tofts P.S., Miller D.H., and McDonald W.I. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 117 (1994) 49-58
106. Davies S.E., Gotoh M., Richards D.A., and Obrenovitch T.P. Hypoosmolarity induces an increase of extracellular N-acetylaspartate concentration in the rat striatum. Neurochem. Res. 23 (1998) 1021-1025
107. De Stefano N., Matthews P.M., and Arnold D.L. Reversible decreases in N-acetylaspartate after acute brain injury. Magn. Reson. Med. 34 (1995) 721-727
108. De Stefano N., Narayanan S., Francis G.S., Arnaoutelis R., Tartaglia M.C., Antel J.P., Matthews P.M., and Arnold D.L. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch. Neurol. 58 (2001) 65-70
109. De Stefano N., Narayanan S., Francis S.J., Smith S., Mortilla M., Tartaglia M.C., Bartolozzi M.L., Guidi L., Federico A., and Arnold D.L. Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability. Arch. Neurol. 59 (2002) 1565-1571
110. Dedeoglu A., Choi J.K., Cormier K., Kowall N.W., and Jenkins B.G. Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile. Brain Res. 1012 (2004) 60-65
111. Deicken R.F., Eliaz Y., Feiwell R., and Schuff N. Increased thalamic N-acetylaspartate in male patients with familial bipolar I disorder. Psychiatry Res. 106 (2001) 35-45
112. Deicken R.F., Johnson C., Eliaz Y., and Schuff N. Reduced concentrations of thalamic N-acetylaspartate in male patients with schizophrenia. Am. J. Psychiatry 157 (2000) 644-647
113. Deicken R.F., Johnson C., and Pegues M. Proton magnetic resonance spectroscopy of the human brain in schizophrenia. Rev. Neurosci. 11 (2000) 147-158
114. Deicken R.F., Zhou L., Schuff N., and Weiner M.W. Proton magnetic resonance spectroscopy of the anterior cingulate region in schizophrenia. Schizophr. Res. 27 (1997) 65-71
115. Demougeot C., Bertrand N., Prigent-Tessier A., Garnier P., Mossiat C., Giroud M., Marie C., and Beley A. Reversible loss of N-acetyl-aspartate in rats subjected to long-term focal cerebral ischemia. J. Cereb. Blood Flow Metab. 23 (2003) 482-489
116. Demougeot C., Garnier P., Mossiat C., Bertrand N., Giroud M., Beley A., and Marie C. N-Acetylaspartate, a marker of both cellular dysfunction and neuronal loss: its relevance to studies of acute brain injury. J. Neurochem. 77 (2001) 408-415
117. Demougeot C., Marie C., Giroud M., and Beley A. N-Acetylaspartate: a literature review of animal research on brain ischaemia. J. Neurochem. 90 (2004) 776-783
118. Di Costanzo A., Trojsi F., Tosetti M., Giannatempo G.M., Nemore F., Piccirillo M., Bonavita S., Tedeschi G., and Scarabino T. High-field proton MRS of human brain. Eur. J. Radiol. 48 (2003) 146-153
119. Divry P., and Mathieu M. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease [letter]. Am. J. Med. Genet. 32 (1989) 550-551
120. Drobyshevsky A., Song S.K., Gamkrelidze G., Wyrwicz A.M., Derrick M., Meng F., Li L., Ji X., Trommer B., Beardsley D.J., Luo N.L., Back S.A., and Tan S. Developmental changes in diffusion anisotropy coincide with immature oligodendrocyte progression and maturation of compound action potential. J. Neurosci. 25 (2005) 5988-5997
121. Duncan I.D. The PLP mutants from mouse to man. J. Neurol. Sci. 228 (2005) 204-205
122. Dupree J.L., Coetzee T., Suzuki K., and Popko B. Myelin abnormalities in mice deficient in galactocerebroside and sulfatide. J. Neurocytol. 27 (1998) 649-659
123. Dupree J.L., and Popko B. Genetic dissection of myelin galactolipid function. J. Neurocytol. 28 (1999) 271-279
124. Egan M.F., Straub R.E., Goldberg T.E., Yakub I., Callicott J.H., Hariri A.R., Mattay V.S., Bertolino A., Hyde T.M., Shannon-Weickert C., Akil M., Crook J., Vakkalanka R.K., Balkissoon R., Gibbs R.A., Kleinman J.E., and Weinberger D.R. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 12604-12609
125. Ende G., Braus D.F., Walter S., Weber-Fahr W., and Henn F.A. Multiregional 1H-MRSI of the hippocampus, thalamus, and basal ganglia in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 253 (2003) 9-15
126. Ende G., Hubrich P., Walter S., Weber-Fahr W., Kammerer N., Braus D.F., and Henn F.A. Further evidence for altered cerebellar neuronal integrity in schizophrenia. Am. J. Psychiatry 162 (2005) 790-792
127. Erecinska M., Zaleska M.M., Nissim I., Nelson D., Dagani F., and Yudkoff M. Glucose and synaptosomal glutamate metabolism: studies with [15N]glutamate. J. Neurochem. 51 (1988) 892-902
128. Estevez A.Y., O'Regan M.H., Song D., and Phillis J.W. Hyposmotically induced amino acid release from the rat cerebral cortex: role of phospholipases and protein kinases. Brain Res. 844 (1999) 1-9
129. Fan G. Comments and controversies: magnetic resonance spectroscopy and gliomas. Cancer Imaging 6 (2006) 113-115
130. Fan T.W., Higashi R.M., Lane A.N., and Jardetzky O. Combined use of 1H-NMR and GC-MS for metabolite monitoring and in vivo 1H-NMR assignments. Biochim. Biophys. Acta 882 (1986) 154-167
131. Faull K.F., Rafie R., Pascoe N., Marsh L., and Pfefferbaum A. N-Acetylaspartic acid (NAA) and N-acetylaspartylglutamic acid (NAAG) in human ventricular, subarachnoid, and lumbar cerebrospinal fluid. Neurochem. Res. 24 (1999) 1249-1261
132. Felipo V., and Butterworth R.F. Neurobiology of ammonia. Prog. Neurobiol. 67 (2002) 259-279
133. Fenstermacher M.J., and Narayana P.A. Serial proton magnetic resonance spectroscopy of ischemic brain injury in humans. Invest. Radiol. 25 (1990) 1034-1039
134. Ferrante R.J., Andreassen O.A., Jenkins B.G., Dedeoglu A., Kuemmerle S., Kubilus J.K., Kaddurah-Daouk R., Hersch S.M., and Beal M.F. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. 20 (2000) 4389-4397
135. Fillenz M. The role of lactate in brain metabolism. Neurochem. Int. 47 (2005) 413-417
136. Franke C., Brinker G., Pillekamp F., and Hoehn M. Probability of metabolic tissue recovery after thrombolytic treatment of experimental stroke: a magnetic resonance spectroscopic imaging study in rat brain. J. Cereb. Blood Flow Metab. 20 (2000) 583-591
137. Fu L., Matthews P.M., De Stefano N., Worsley K.J., Narayanan S., Francis G.S., Antel J.P., Wolfson C., and Arnold D.L. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 121 Pt 1 (1998) 103-113
138. Fujita N., Kemper A., Dupree J., Nakayasu H., Bartsch U., Schachner M., Maeda N., Suzuki K., and Popko B. The cytoplasmic domain of the large myelin-associated glycoprotein isoform is needed for proper CNS but not peripheral nervous system myelination. J. Neurosci. 18 (1998) 1970-1978
139. Fujita T., Katsukawa H., Yodoya E., Wada M., Shimada A., Okada N., Yamamoto A., and Ganapathy V. Transport characteristics of N-acetyl-l-aspartate in rat astrocytes: involvement of sodium-coupled high-affinity carboxylate transporter NaC3/NaDC3-mediated transport system. J. Neurochem. 93 (2005) 706-714
140. Fulham M.J., Bizzi A., Dietz M.J., Shih H.H., Raman R., Sobering G.S., Frank J.A., Dwyer A.J., Alger J.R., and Di Chiro G. Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance. Radiology 185 (1992) 675-686
141. Ganapathy V., and Fujita T. Identity of the high-affinity sodium/carboxylate cotransporter NaC3 as the N-acetyl-l-aspartate transporter. In: Moffett J.R., Tieman S.B., Weinberger D.R., Coyle J.T., and Namboodiri M.A. (Eds). N-Acetylaspartate: A Unique Neuronal Molecule in the Central Nervous System (2006), Springer Science, New York, NY 67-76
142. Garbern J.Y. Pelizaeus-Merzbacher disease: pathogenic mechanisms and insights into the roles of proteolipid protein 1 in the nervous system. J. Neurol. Sci. 228 (2005) 201-203
143. Gasparovic C., Arfai N., Smid N., and Feeney D.M. Decrease and recovery of N-acetylaspartate/creatine in rat brain remote from focal injury. J. Neurotrauma 18 (2001) 241-246
144. Gehl L.M., Saab O.H., Bzdega T., Wroblewska B., and Neale J.H. Biosynthesis of NAAG by an enzyme-mediated process in rat central nervous system neurons and glia. J. Neurochem. 90 (2004) 989-997
145. George R.L., Huang W., Naggar H.A., Smith S.B., and Ganapathy V. Transport of N-acetylaspartate via murine sodium/dicarboxylate cotransporter NaDC3 and expression of this transporter and aspartoacylase II in ocular tissues in mouse. Biochim. Biophys. Acta 1690 (2004) 63-69
146. Gideon P., Sperling B., rlien-Soborg P., Olsen T.S., and Henriksen O. Long-term follow-up of cerebral infarction patients with proton magnetic resonance spectroscopy. Stroke 25 (1994) 967-973
147. Gillard J.H., Waldman A.D., and Barker P.B. Clinical MR Neuroimaging (Diffusion, Perfusion and Spectroscopy) (2005), Cambridge University Press, Cambridge, UK
148. Girard N., Fogliarini C., Viola A., Confort-Gouny S., Fur Y.L., Viout P., Chapon F., Levrier O., and Cozzone P. MRS of normal and impaired fetal brain development. Eur. J. Radiol 57 2 (2005) 217-225
149. Godbolt A.K., Waldman A.D., MacManus D.G., Schott J.M., Frost C., Cipolotti L., Fox N.C., and Rossor M.N. MRS shows abnormalities before symptoms in familial Alzheimer disease. Neurology 66 (2006) 718-722
150. Goldberg R.P., and Brunengraber H. Contributions of cytosolic and mitochondrial acetyl-CoA syntheses to the activation of lipogenic acetate in rat liver. Adv. Exp. Med. Biol. 132 (1980) 413-418
151. Goldstein F.B. Biosynthesis of N-acetyl-l-aspartic acid. Biochim. Biophys. Acta 33 (1959) 583-584
152. Goldstein F.B. The enzymatic synthesis of N-acetyl-l-aspartic acid by subcellular preparations of rat brain. J. Biol. Chem. 244 (1969) 4257-4260
153. Gotoh M., Davies S.E., and Obrenovitch T.P. Brain tissue acidosis: effects on the extracellular concentration of N-acetylaspartate. J. Neurochem. 69 (1997) 655-661
154. Gow A., Southwood C.M., and Lazzarini R.A. Disrupted proteolipid protein trafficking results in oligodendrocyte apoptosis in an animal model of Pelizaeus-Merzbacher disease. J. Cell Biol. 140 (1998) 925-934
155. Graham G.D., Blamire A.M., Rothman D.L., Brass L.M., Fayad P.B., Petroff O.A., and Prichard J.W. Early temporal variation of cerebral metabolites after human stroke. A proton magnetic resonance spectroscopy study. Stroke 24 (1993) 1891-1896
156. Graham S.H., Meyerhoff D.J., Bayne L., Sharp F.R., and Weiner M.W. Magnetic resonance spectroscopy of N-acetylaspartate in hypoxic-ischemic encephalopathy. Ann. Neurol. 35 (1994) 490-494
157. Gujar S.K., Maheshwari S., Bjorkman-Burtscher I., and Sundgren P.C. Magnetic resonance spectroscopy. J. Neuroophthalmol. 25 (2005) 217-226
158. Gullans S.R., and Verbalis J.G. Control of brain volume during hyperosmolar and hypoosmolar conditions. Annu. Rev. Med. 44 (1993) 289-301
159. Hagenfeldt L., Bollgren I., and Venizelos N. N-Acetylaspartic aciduria due to aspartoacylase deficiency-a new aetiology of childhood leukodystrophy. J. Inherit. Metab. Dis. 10 (1987) 135-141
160. Hamosh A., Scott A.F., Amberger J.S., Bocchini C.A., and McKusick V.A. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res. 33 (2005) D514-D517
161. Hanefeld F.A., Brockmann K., Pouwels P.J., Wilken B., Frahm J., and Dechent P. Quantitative proton MRS of Pelizaeus-Merzbacher disease: evidence of dys- and hypomyelination. Neurology 65 (2005) 701-706
162. Harada M., Tanouchi M., Miyoshi H., Nishitani H., and Kannuki S. Brain abscess observed by localized proton magnetic resonance spectroscopy. Magn. Reson. Imaging 12 (1994) 1269-1274
163. Harris K., Lin A., Bhattacharya P., Tran T., Wong W., and Ross B.D. Regulation of NAA-synthesis in the human brain in vivo: Canavan's disease, Alzheimer's disease and schizophrenia. In: Moffett J.R., Tieman S.B., Weinberger D.R., Coyle J.T., and Namboodiri M.A. (Eds). N-Acetylaspartate: A Unique Neuronal Molecule in the Central Nervous System (2006), Springer Science, New York, NY 263-273
164. Harte M.K., Bachus S.B., and Reynolds G.P. Increased N-acetylaspartate in rat striatum following long-term administration of haloperidol. Schizophr. Res. 75 (2005) 303-308
165. Haseler L.J., Arcinue E., Danielsen E.R., Bluml S., and Ross B.D. Evidence from proton magnetic resonance spectroscopy for a metabolic cascade of neuronal damage in shaken baby syndrome. Pediatrics 99 (1997) 4-14
166. Hassel B., Sonnewald U., and Fonnum F. Glial-neuronal interactions as studied by cerebral metabolism of [2-13C]acetate and [1-13C]glucose: an ex vivo 13C NMR spectroscopic study. J. Neurochem. 64 (1995) 2773-2782
167. Heilig C.W., Stromski M.E., Blumenfeld J.D., Lee J.P., and Gullans S.R. Characterization of the major brain osmolytes that accumulate in salt-loaded rats. Am. J. Physiol. 257 (1989) F1108-F1116
168. Hershfield J., Madhavarao C.N., Moffett J.R., Benjamins J.A., Garbern J.Y., and Namboodiri M.A. Aspartoacylase is a regulated nuclear-cytoplasmic enzyme. FASEB J. 20 12 (2006) 2139-2141
169. Higuchi T., Fernandez E.J., Maudsley A.A., Shimizu H., Weiner M.W., and Weinstein P.R. Mapping of lactate and N-acetyl-l-aspartate predicts infarction during acute focal ischemia: in vivo 1H magnetic resonance spectroscopy in rats. Neurosurgery 38 (1996) 121-129
170. Hoehn M., Nicolay K., Franke C., and van der S.B. Application of magnetic resonance to animal models of cerebral ischemia. J. Magn. Reson. Imaging 14 (2001) 491-509
171. Hogan G.R., and Richardson Jr. E.P. Spongy degeneration of the nervous system (Canavan's disease). Pediatrics 35 (1965) 284-294
172. Hou J., and Major E.O. Progressive multifocal leukoencephalopathy: JC virus induced demyelination in the immune compromised host. J. Neurovirol. 6 Suppl. 2 (2000) S98-S100
173. Huang W., Wang H., Kekuda R., Fei Y.J., Friedrich A., Wang J., Conway S.J., Cameron R.S., Leibach F.H., and Ganapathy V. Transport of N-acetylaspartate by the Na(+)-dependent high-affinity dicarboxylate transporter NaDC3 and its relevance to the expression of the transporter in the brain. J. Pharmacol. Exp. Ther. 295 (2000) 392-403
174. Jack Jr. C.R., Garwood M., Wengenack T.M., Borowski B., Curran G.L., Lin J., Adriany G., Grohn O.H., Grimm R., and Poduslo J.F. In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. Magn. Reson. Med. 52 (2004) 1263-1271
175. Jack Jr. C.R., Wengenack T.M., Reyes D.A., Garwood M., Curran G.L., Borowski B.J., Lin J., Preboske G.M., Holasek S.S., Adriany G., and Poduslo J.F. In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer's transgenic mice. J. Neurosci. 25 (2005) 10041-10048
176. Jagannathan N.R., Desai N.G., and Raghunathan P. Brain metabolite changes in alcoholism: an in vivo proton magnetic resonance spectroscopy (MRS) study. Magn. Reson. Imaging 14 (1996) 553-557
177. Jakary A., Vinogradov S., Feiwell R., and Deicken R.F. N-Acetylaspartate reductions in the mediodorsal and anterior thalamus in men with schizophrenia verified by tissue volume corrected proton MRSI. Schizophr. Res. 76 (2005) 173-185
178. Jalil M.A., Begum L., Contreras L., Pardo B., Iijima M., Li M.X., Ramos M., Marmol P., Horiuchi M., Shimotsu K., Nakagawa S., Okubo A., Sameshima M., Isashiki Y., Del Arco A., Kobayashi K., Satrustegui J., and Saheki T. Reduced N-acetylaspartate levels in mice lacking Aralar, a brain-and muscle-type mitochondrial aspartate-glutamate carrier. J. Biol. Chem. 280 (2005) 31333-31339
179. Jambou D., and Lapalus P. Effect of N-acetyl-aspartyl-glutamate (Naaga) on in-vitro leukotriene synthesis by macrophage cell line P388D1. Int. J. Tissue React. 12 (1990) 273-280
180. Janson C., McPhee S., Bilaniuk L., Haselgrove J., Testaiuti M., Freese A., Wang D.J., Shera D., Hurh P., Rupin J., Saslow E., Goldfarb O., Goldberg M., Larijani G., Sharrar W., Liouterman L., Camp A., Kolodny E., Samulski J., and Leone P. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum. Gene Ther. 13 (2002) 1391-1412
181. Jayasundar R., Shah T., Vaishya S., Singh V.P., and Sarkar C. In vivo and in vitro MR spectroscopic profile of central neurocytomas. J. Magn. Reson. Imaging 17 (2003) 256-260
182. Jenkins B.G., Klivenyi P., Kustermann E., Andreassen O.A., Ferrante R.J., Rosen B.R., and Beal M.F. Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. J. Neurochem. 74 (2000) 2108-2119
183. Jessen F., Scherk H., Traber F., Theyson S., Berning J., Tepest R., Falkai P., Schild H.H., Maier W., Wagner M., and Block W. Proton magnetic resonance spectroscopy in subjects at risk for schizophrenia. Schizophr. Res 87 1-3 (2006) 81-88
184. Jiang H., Duchala C.S., Awatramani R., Shumas S., Carlock L., Kamholz J., Garbern J., Scherer S.S., Shy M.E., and Macklin W.B. Proteolipid protein mRNA stability is regulated by axonal contact in the rodent peripheral nervous system. J. Neurobiol. 44 (2000) 7-19
185. Jones C.T., and Ashton I.K. Lipid biosynthesis in liver slices of the foetal guinea pig. Biochem. J. 154 (1976) 149-158
186. Jung R.E., Haier R.J., Yeo R.A., Rowland L.M., Petropoulos H., Levine A.S., Sibbitt W.L., and Brooks W.M. Sex differences in N-acetylaspartate correlates of general intelligence: an 1H-MRS study of normal human brain. Neuroimage 26 (2005) 965-972
187. Kadota O., Kohno K., Ohue S., Kumon Y., Sakaki S., Kikuchi K., and Miki H. Discrimination of brain abscess and cystic tumor by in vivo proton magnetic resonance spectroscopy. Neurol. Med. Chir. (Tokyo) 41 (2001) 121-126
188. Kalra S., and Arnold D.L. ALS surrogate markers. MRS. Amyotroph. Lateral. Scler. Other Motor Neuron Disord. 5 Suppl. 1 (2004) 111-114
189. Kalra S., and Arnold D.L. Magnetic resonance spectroscopy for monitoring neuronal integrity in amyotrophic lateral sclerosis. In: Moffett J.R., Tieman S.B., Weinberger D.R., Coyle J.T., and Namboodiri M.A. (Eds). N-Acetylaspartate: A Unique Neuronal Molecule in the Central Nervous System (2006), Springer Science, New York, NY 275-282
190. Kalra S., Cashman N.R., Genge A., and Arnold D.L. Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. Neuroreport 9 (1998) 1757-1761
191. Kantarci K., and Jack Jr. C.R. Neuroimaging in Alzheimer disease: an evidence-based review. Neuroimaging Clin. N. Am. 13 (2003) 197-209
192. Kantarci K., Jack Jr. C.R., Xu Y.C., Campeau N.G., O'Brien P.C., Smith G.E., Ivnik R.J., Boeve B.F., Kokmen E., Tangalos E.G., and Petersen R.C. Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1H MRS study. Neurology 55 (2000) 210-217
193. Kantarci K., Reynolds G., Petersen R.C., Boeve B.F., Knopman D.S., Edland S.D., Smith G.E., Ivnik R.J., Tangalos E.G., and Jack Jr. C.R. Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T. AJNR Am. J. Neuroradiol. 24 (2003) 843-849
194. Kantarci K., Xu Y., Shiung M.M., O'Brien P.C., Cha R.H., Smith G.E., Ivnik R.J., Boeve B.F., Edland S.D., Kokmen E., Tangalos E.G., Petersen R.C., and Jack Jr. C.R. Comparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 14 (2002) 198-207
195. Karelson G., Ziegler A., Kunnecke B., and Seelig J. Feeding versus infusion: a novel approach to study the NAA metabolism in rat brain. NMR Biomed. 16 (2003) 413-423
196. Kaul R., Balamurugan K., Gao G.P., and Matalon R. Canavan disease: genomic organization and localization of human ASPA to 17p13-ter and conservation of the ASPA gene during evolution. Genomics 21 (1994) 364-370
197. Kaul R., Casanova J., Johnson A.B., Tang P., and Matalon R. Purification, characterization, and localization of aspartoacylase from bovine brain. J. Neurochem. 56 (1991) 129-135
198. Kaul R., Gao G.P., Aloya M., Balamurugan K., Petrosky A., Michals K., and Matalon R. Canavan disease: mutations among Jewish and non-jewish patients. Am. J. Hum. Genet. 55 (1994) 34-41
199. Kaul R., Gao G.P., Balamurugan K., and Matalon R. Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease. Nat. Genet. 5 (1993) 118-123
200. Kaul R., Gao G.P., Matalon R., Aloya M., Su Q., Jin M., Johnson A.B., Schutgens R.B., and Clarke J.T. Identification and expression of eight novel mutations among non-Jewish patients with Canavan disease. Am. J. Hum. Genet. 59 (1996) 95-102
201. Kelley R.I., and Stamas J.N. Quantification of N-acetyl-l-aspartic acid in urine by isotope dilution gas chromatography-mass spectrometry. J. Inherit. Metab. Dis. 15 (1992) 97-104
202. Keshavan M.S., Stanley J.A., and Pettegrew J.W. Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings-part II. Biol. Psychiatry 48 (2000) 369-380
203. Khan O., Shen Y., Caon C., Bao F., Ching W., Reznar M., Buccheister A., Hu J., Latif Z., Tselis A., and Lisak R. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult. Scler. 11 (2005) 646-651
204. Kirmani B.F., Jacobowitz D.M., Kallarakal A.T., and Namboodiri M.A. Aspartoacylase is restricted primarily to myelin synthesizing cells in the CNS: therapeutic implications for Canavan disease. Brain Res. Mol. Brain Res. 107 (2002) 176-182
205. Kirmani B.F., Jacobowitz D.M., and Namboodiri M.A. Developmental increase of aspartoacylase in oligodendrocytes parallels CNS myelination. Brain Res. Dev. Brain Res. 140 (2003) 105-115
206. Kitada K., Akimitsu T., Shigematsu Y., Kondo A., Maihara T., Yokoi N., Kuramoto T., Sasa M., and Serikawa T. Accumulation of N-acetyl-l-aspartate in the brain of the tremor rat, a mutant exhibiting absence-like seizure and spongiform degeneration in the central nervous system. J. Neurochem. 74 (2000) 2512-2519
207. Klugmann M., Leichtlein C.B., Symes C.W., Serikawa T., Young D., and During M.J. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease. Mol. Ther. 11 (2005) 745-753
208. Klugmann M., Symes C.W., Klaussner B.K., Leichtlein C.B., Serikawa T., Young D., and During M.J. Identification and distribution of aspartoacylase in the postnatal rat brain. Neuroreport 14 (2003) 1837-1840
209. Knizley Jr. H. The enzymatic synthesis of N-acetyl-l-aspartic acid by a water-insoluble preparation of a cat brain acetone powder. J. Biol. Chem. 242 (1967) 4619-4622
210. Kondo A., Nagara H., Akazawa K., Tateishi J., Serikawa T., and Yamada J. CNS pathology in the neurological mutant rats zitter, tremor and zitter-tremor double mutant (spontaneously epileptic rat, SER). Exaggeration of clinical and neuropathological phenotypes in SER. Brain 114 Pt 2 (1991) 979-999
211. Kreis R., Arcinue E., Ernst T., Shonk T.K., Flores R., and Ross B.D. Hypoxic encephalopathy after near-drowning studied by quantitative 1H-magnetic resonance spectroscopy. J. Clin. Invest. 97 (1996) 1142-1154
212. Kvittingen E.A., Guldal G., Borsting S., Skalpe I.O., Stokke O., and Jellum E. N-Acetylaspartic aciduria in a child with a progressive cerebral atrophy. Clin. Chim. Acta 158 (1986) 217-227
213. Lapalus P., Moulin G., Bayer V., Fredj-Reygrobellet D., and Elena P.P. Effects of a new anti-allergic agent: the magnesium salt of N-acetyl-aspartyl-glutamic acid on experimental allergic inflammation of the rabbit eye. Curr. Eye Res. 5 (1986) 517-522
214. Larsson H.B., Christiansen P., Jensen M., Frederiksen J., Heltberg A., Olesen J., and Henriksen O. Localized in vivo proton spectroscopy in the brain of patients with multiple sclerosis. Magn. Reson. Med. 22 (1991) 23-31
215. Leary S.M., Davie C.A., Parker G.J., Stevenson V.L., Wang L., Barker G.J., Miller D.H., and Thompson A.J. 1H magnetic resonance spectroscopy of normal appearing white matter in primary progressive multiple sclerosis. J. Neurol. 246 (1999) 1023-1026
216. Lebon V., Petersen K.F., Cline G.W., Shen J., Mason G.F., Dufour S., Behar K.L., Shulman G.I., and Rothman D.L. Astroglial contribution to brain energy metabolism in humans revealed by 13C nuclear magnetic resonance spectroscopy: elucidation of the dominant pathway for neurotransmitter glutamate repletion and measurement of astrocytic oxidative metabolism. J. Neurosci. 22 (2002) 1523-1531
217. Ledeen R.W., Wang J., Wu G., Lu Z.H., Chakraborty G., Meyenhofer M., Tyring S.K., and Matalon R. Physiological role of N-acetylaspartate: contribution to myelinogenesis. In: Moffett J.R., Tieman S.B., Weinberger D.R., Coyle J.T., and Namboodiri M.A. (Eds). N-Acetylaspartate: A Unique Neuronal Molecule in the Central Nervous System (2006), Springer Science, New York, NY 131-143
218. Lee V.M., Burdett N.G., Carpenter A., Hall L.D., Pambakian P.S., Patel S., Wood N.I., and James M.F. Evolution of photochemically induced focal cerebral ischemia in the rat. Magnetic resonance imaging and histology. Stroke 27 (1996) 2110-2118
219. Lee W.T., Lee C.S., Pan Y.L., and Chang C. Temporal changes of cerebral metabolites and striatal lesions in acute 3-nitropropionic acid intoxication in the rat. Magn. Reson. Med. 44 (2000) 29-34
220. Leone P., Janson C.G., Bilaniuk L., Wang Z., Sorgi F., Huang L., Matalon R., Kaul R., Zeng Z., Freese A., McPhee S.W., Mee E., During M.J., and Bilianuk L. Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease. Ann. Neurol. 48 (2000) 27-38
221. Leone P., Janson C.G., McPhee S.J., and During M.J. Global CNS gene transfer for a childhood neurogenetic enzyme deficiency: Canavan disease. Curr. Opin. Mol. Ther. 1 (1999) 487-492
222. Lieberman E.M., Achreja M., and Urazaev A.K. Synthesis of N-acetylaspartyl-glutamate (NAAG) and N-acetylaspartate (NAA) in axons and glia of the crayfish medial giant nerve fiber. In: Moffett J.R., Tieman S.B., Weinberger D.R., Coyle J.T., and Namboodiri M.A. (Eds). N-Acetylaspartate: A Unique Neuronal Molecule in the Central Nervous System (2006), Springer Science, New York, NY 303-315
223. Lin A., Ross B.D., Harris K., and Wong W. Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making. NeuroRx 2 (2005) 197-214
224. Lin A.P., Shic F., Enriquez C., and Ross B.D. Reduced glutamate neurotransmission in patients with Alzheimer's disease-an in vivo (13)C magnetic resonance spectroscopy study. MAGMA 16 (2003) 29-42
225. Lin D.D., Crawford T.O., and Barker P.B. Proton MR spectroscopy in the diagnostic evaluation of suspected mitochondrial disease. AJNR Am. J. Neuroradiol. 24 (2003) 33-41
226. Lu Z.H., Chakraborty G., Ledeen R.W., Yahya D., and Wu G. N-Acetylaspartate synthase is bimodally expressed in microsomes and mitochondria of brain. Brain Res. Mol. Brain Res. 122 (2004) 71-78
227. Luong A., Hannah V.C., Brown M.S., and Goldstein J.L. Molecular characterization of human acetyl-CoA synthetase, an enzyme regulated by sterol regulatory element-binding proteins. J. Biol. Chem. 275 (2000) 26458-26466
228. Luyten P.R., and den Hollander J.A. Observation of metabolites in the human brain by MR spectroscopy. Radiology 161 (1986) 795-798
229. Madhavarao C.N., Arun P., Moffett J.R., Szucs S., Surendran S., Matalon R., Garbern J., Hristova D., Johnson A., Jiang W., and Namboodiri M.A. Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 5221-5226
230. Madhavarao C.N., Chinopoulos C., Chandrasekaran K., and Namboodiri M.A. Characterization of the N-acetylaspartate biosynthetic enzyme from rat brain. J. Neurochem. 86 (2003) 824-835
231. Madhavarao C.N., Hammer J.A., Quarles R.H., and Namboodiri M.A. A radiometric assay for aspartoacylase activity in cultured oligodendrocytes. Anal. Biochem. 308 (2002) 314-319
232. Madhavarao C.N., Moffett J.R., Moore R.A., Viola R.E., Namboodiri M.A., and Jacobowitz D.M. Immunohistochemical localization of aspartoacylase in the rat central nervous system. J. Comp. Neurol. 472 (2004) 318-329
233. Madhavarao C.N., and Namboodiri A.M. NAA synthesis and functional roles. In: Moffett J.R., Tieman S.B., Weinberger D.R., Coyle J.T., and Namboodiri M.A. (Eds). N-Acetylaspartate: A Unique Neuronal Molecule in the Central Nervous System (2006), Springer Science, New York, NY 49-66
234. Marenco S., Bertolino A., and Weinberger D.R. MR proton spectroscopy. In: Lawrie S.M., Johnstone E.C., and Weinberger D.R. (Eds). Schizophrenia: From Neuroimaging to Neuroscience (2004), Oxford University Press, Oxford, UK 73-92
235. Marenco S., Bertolino A., and Weinberger D.R. In vivo NMR measures of NAA and the neurobiology of schizophrenia. In: Moffett J.R., Tieman S.B., Weinberger D.R., Coyle J.T., and Namboodiri M.A. (Eds). N-Acetylaspartate: A Unique Neuronal Molecule in the Central Nervous System (2006), Springer Science, New York, NY 227-240
236. Marenco S., Steele S.U., Egan M.F., Goldberg T.E., Straub R.E., Sharrief A.Z., and Weinberger D.R. Effect of metabotropic glutamate receptor 3 genotype on N-acetylaspartate measures in the dorsolateral prefrontal cortex. Am. J. Psychiatry 163 (2006) 740-742
237. Margolis R.U., Barkulis S.S., and Geiger A. A comparison between the incorporation of 14C from glucose into N-acetyly-l-aspartic acid and aspartic acid in brain perfusion experiments. J. Neurochem. 5 (1960) 379-382
238. Maria B.L., Deidrick K.M., Moser H., and Naidu S. Leukodystrophies: pathogenesis, diagnosis, strategies, therapies, and future research directions. J. Child Neurol. 18 (2003) 578-590
239. Martinez-Hernandez A., Bell K.P., and Norenberg M.D. Glutamine synthetase: glial localization in brain. Science 195 (1977) 1356-1358
240. Mastorodemos V., Zaganas I., Spanaki C., Bessa M., and Plaitakis A. Molecular basis of human glutamate dehydrogenase regulation under changing energy demands. J. Neurosci. Res. 79 (2005) 65-73
241. Matalon R., Michals K., and Kaul R. Canavan disease: from spongy degeneration to molecular analysis. J. Pediatr. 127 (1995) 511-517
242. Matalon R., Michals K., Sebesta D., Deanching M., Gashkoff P., and Casanova J. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with canavan disease. Am. J. Med. Genet. 29 (1988) 463-471
243. Matalon R., and Michals-Matalon K. Molecular basis of Canavan disease. Eur. J. Paediatr. Neurol. 2 (1998) 69-76
244. Matalon R., Rady P.L., Platt K.A., Skinner H.B., Quast M.J., Campbell G.A., Matalon K., Ceci J.D., Tyring S.K., Nehls M., Surendran S., Wei J., Ezell E.L., and Szucs S. Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system. J. Gene Med. 2 (2000) 165-175
245. Matalon R., Surendran S., Rady P.L., Quast M.J., Campbell G.A., Matalon K.M., Tyring S.K., Wei J., Peden C.S., Ezell E.L., Muzyczka N., and Mandel R.J. Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease. Mol. Ther. 7 (2003) 580-587
246. Mathew R., Arun P., Madhavarao C., Moffett J., and Namboodiri A. Progress toward acetate supplementation therapy for Canavan disease: glyceryl triacetate administration increases acetate, but not N-acetylaspartate levels in brain. J. Pharmacol. Exp. Ther. 315 (2005) 297-303
247. Mathiesen H.K., Jonsson A., Tscherning T., Hanson L.G., Andresen J., Blinkenberg M., Paulson O.B., and Sorensen P.S. Correlation of global N-acetyl aspartate with cognitive impairment in multiple sclerosis. Arch. Neurol. 63 (2006) 533-536
248. McIntosh J.C., and Cooper J.R. Studies on the function of N-acetyl aspartic acid in brain. J. Neurochem. 12 (1965) 825-835
249. McKenna M.C., Stevenson J.H., Huang X., and Hopkins I.B. Differential distribution of the enzymes glutamate dehydrogenase and aspartate aminotransferase in cortical synaptic mitochondria contributes to metabolic compartmentation in cortical synaptic terminals. Neurochem. Int. 37 (2000) 229-241
250. McPhee S.W., Francis J., Janson C.G., Serikawa T., Hyland K., Ong E.O., Raghavan S.S., Freese A., and Leone P. Effects of AAV-2-mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease. Brain Res. Mol. Brain Res. 135 (2005) 112-121
251. Mehta V., and Namboodiri M.A. N-acetylaspartate as an acetyl source in the nervous system. Brain Res. Mol. Brain Res. 31 (1995) 151-157
252. Menichella D.M., Goodenough D.A., Sirkowski E., Scherer S.S., and Paul D.L. Connexins are critical for normal myelination in the CNS. J. Neurosci. 23 (2003) 5963-5973
253. Menon D.K., Sargentoni J., Peden C.J., Bell J.D., Cox I.J., Coutts G.A., Baudouin C., and Newman C.G. Proton MR spectroscopy in herpes simplex encephalitis: assessment of neuronal loss. J. Comput. Assist. Tomogr. 14 (1990) 449-452
254. Meyerhoff D.J., Blumenfeld R., Truran D., Lindgren J., Flenniken D., Cardenas V., Chao L.L., Rothlind J., Studholme C., and Weiner M.W. Effects of heavy drinking, binge drinking, and family history of alcoholism on regional brain metabolites. Alcohol Clin. Exp. Res. 28 (2004) 650-661
255. Meyerhoff D.J., MacKay S., Bachman L., Poole N., Dillon W.P., Weiner M.W., and Fein G. Reduced brain N-acetylaspartate suggests neuronal loss in cognitively impaired human immunodeficiency virus-seropositive individuals: in vivo 1H magnetic resonance spectroscopic imaging. Neurology 43 (1993) 509-515
256. Miadonna A., Milazzo N., Salmaso C., Cottini M., Lorini M., and Tedeschi A. N-acetyl-aspartyl-glutamic acid inhibits cellular recruitment and mediator release during the late allergen-induced nasal reaction. Eur. J. Clin. Pharmacol. 54 (1998) 515-520
257. Miller S.L., Daikhin Y., and Yudkoff M. Metabolism of N-acetyl-l-aspartate in rat brain. Neurochem. Res. 21 (1996) 615-618
258. Miyake M., Kakimoto Y., and Sorimachi M. A gas chromatographic method for the determination of N-acetyl-l-aspartic acid, N-acetyl-aspartylglutamic acid and beta-citryl-l-glutamic acid and their distributions in the brain and other organs of various species of animals. J. Neurochem. 36 (1981) 804-810
259. Miyake M., Morino H., Mizobuchi M., and Kakimoto Y. N-acetyl-l-aspartic acid, N-acetyl-alpha-l-aspartyl-l-glutamic acid and beta-citryl-l-glutamic acid in human urine. Clin. Chim. Acta 120 (1982) 119-126
260. Moats R.A., Ernst T., Shonk T.K., and Ross B.D. Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn. Reson. Med. 32 (1994) 110-115
261. Moffett J.R., and Namboodiri M.A. Differential distribution of N-acetylaspartylglutamate and N-acetylaspartate immunoreactivities in rat forebrain. J. Neurocytol. 24 (1995) 409-433
262. Moffett J.R., and Namboodiri M.A. Expression of N-acetylaspartate and N-acetylaspartylglutamate in the nervous system. In: Moffett J.R., Tieman S.B., Weinberger D.R., Coyle J.T., and Namboodiri M.A. (Eds). N-Acetylaspartate: A Unique Neuronal Molecule in the Central Nervous System (2006), Springer Science, New York, NY 7-26
263. Moffett J.R., Namboodiri M.A., Cangro C.B., and Neale J.H. Immunohistochemical localization of N-acetylaspartate in rat brain. Neuroreport 2 (1991) 131-134
264. Moffett J.R., Namboodiri M.A., and Neale J.H. Enhanced carbodiimide fixation for immunohistochemistry: application to the comparative distributions of N-acetylaspartylglutamate and N-acetylaspartate immunoreactivities in rat brain. J. Histochem. Cytochem. 41 (1993) 559-570
265. Moffett J.R., Tieman S.B., Weinberger D.R., Coyle J.T., and Namboodiri M.A. N-Acetylaspartate: A Unique Neuronal Molecule in the Central Nervous System (2006), Springer Science, New York, NY
266. Moghaddam B. Bringing order to the glutamate chaos in schizophrenia. Neuron 40 (2003) 881-884
267. Moghaddam B., and Jackson M.E. Glutamatergic animal models of schizophrenia. Ann. N.Y. Acad. Sci. 1003 (2003) 131-137
268. Moore R.A., Le Coq J., Faehnle C.R., and Viola R.E. Purification and preliminary characterization of brain aspartoacylase. Arch. Biochem. Biophys. 413 (2003) 1-8
269. Moreno A., Ross B.D., and Bluml S. Direct determination of the N-acetyl-l-aspartate synthesis rate in the human brain by (13)C MRS and [1-(13)C]glucose infusion. J. Neurochem. 77 (2001) 347-350
270. Mostert J.P., Sijens P.E., Oudkerk M., and De K.J. Fluoxetine increases cerebral white matter NAA/Cr ratio in patients with multiple sclerosis. Neurosci. Lett. 402 (2006) 22-24
271. Muir D., Berl S., and Clarke D.D. Acetate and fluoroacetate as possible markers for glial metabolism in vivo. Brain Res. 380 (1986) 336-340
272. Muse E.D., Jurevics H., Toews A.D., Matsushima G.K., and Morell P. Parameters related to lipid metabolism as markers of myelination in mouse brain. J. Neurochem. 76 (2001) 77-86
273. Nadler J.V., and Cooper J.R. Metabolism of the aspartyl moiety of N-acetyl-l-aspartic acid in the rat brain. J. Neurochem. 19 (1972) 2091-2105
274. Nadler J.V., and Cooper J.R. N-acetyl-l-aspartic acid content of human neural tumours and bovine peripheral nervous tissues. J. Neurochem. 19 (1972) 313-319
275. Nakaiso M., Uno M., Harada M., Kageji T., Takimoto O., and Nagahiro S. Brain abscess and glioblastoma identified by combined proton magnetic resonance spectroscopy and diffusion-weighted magnetic resonance imaging-two case reports. Neurol. Med. Chir (Tokyo) 42 (2002) 346-348
276. Namboodiri M.A., Corigliano-Murphy A., Jiang G., Rollag M., and Provencio I. Murine aspartoacylase: cloning, expression and comparison with the human enzyme. Brain Res. Mol. Brain Res. 77 (2000) 285-289
277. Namboodiri M.A., Moffett J.R., Arun P., Mathew R., Namboodiri S., Potti A., Hershfield J., Kirmani B., Jacobowitz D.M., and Madhavarao C.N. Defective myelin lipid synthesis as a pathogenic mechanism of Canavan disease. In: Moffett J.R., Tieman S.B., Weinberger D.R., Coyle J.T., and Namboodiri M.A. (Eds). N-Acetylaspartate: A Unique Neuronal Molecule in the Central Nervous System (2006), Springer Science, New York, NY 145-163
278. Namboodiri M.A., Peethambaran A., Mathew R., Sambhu P.A., Hershfield J., Moffett J.R., and Madhavarao C.N. Canavan disease and the role of N-acetylaspartate in myelin synthesis. Mol. Cell Endocrinol. 252 (2006) 216-223
279. Narayanan S., De Stefano N., Francis G.S., Arnaoutelis R., Caramanos Z., Collins D.L., Pelletier D., Arnason B.G.W., Antel J.P., and Arnold D.L. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J. Neurol. 248 (2001) 979-986
280. Nikolau B.J., Oliver D.J., Schnable P.S., and Wurtele E.S. Molecular biology of acetyl-CoA metabolism. Biochem. Soc. Trans. 28 (2000) 591-593
281. Norenberg M.D., and Martinez-Hernandez A. Fine structural localization of glutamine synthetase in astrocytes of rat brain. Brain Res. 161 (1979) 303-310
282. Odermatt B., Wellershaus K., Wallraff A., Seifert G., Degen J., Euwens C., Fuss B., Bussow H., Schilling K., Steinhauser C., and Willecke K. Connexin 47 (Cx47)-deficient mice with enhanced green fluorescent protein reporter gene reveal predominant oligodendrocytic expression of Cx47 and display vacuolized myelin in the CNS. J. Neurosci. 23 (2003) 4549-4559
283. Ohrmann, P., Siegmund, A., Suslow, T., Pedersen, A., Spitzberg, K., Kersting, A., Rothermundt, M., Arolt, V., Heindel, W., Pfleiderer, B., 2006. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study. J. Psychiatr. Res., in press.
284. Ohrmann P., Siegmund A., Suslow T., Spitzberg K., Kersting A., Arolt V., Heindel W., and Pfleiderer B. Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study. Schizophr. Res. 73 (2005) 153-157
285. Oppenheim C., Zuber M., Galanaud D., Detilleux M., Bolgert F., Mas J.L., Chiras J., and Meder J.F. Spectroscopy and serial diffusion MR findings in hGH-Creutzfeldt-Jakob disease. J. Neurol. Neurosurg. Psychiatry 75 (2004) 1066-1069
286. Owen O.E., Kalhan S.C., and Hanson R.W. The key role of anaplerosis and cataplerosis for citric acid cycle function. J. Biol. Chem. 277 (2002) 30409-30412
287. Paley M., Cozzone P.J., Alonso J., Vion-Dury J., Confort-Gouny S., Wilkinson I.D., Chong W.K., Hall-Craggs M.A., Harrison M.J., Gili J., Rovira A., Capellades J., Rio J., Ocana I., Nicoli F., Dhiver C., Gastaut J.L., Gastaut J.A., Wicklow K., and Sauter R. A multicenter proton magnetic resonance spectroscopy study of neurological complications of AIDS. AIDS Res. Hum. Retroviruses 12 (1996) 213-222
288. Pan J.W., and Takahashi K. Interdependence of N-acetyl aspartate and high-energy phosphates in healthy human brain. Ann. Neurol. 57 (2005) 92-97
289. Parks M.H., Dawant B.M., Riddle W.R., Hartmann S.L., Dietrich M.S., Nickel M.K., Price R.R., and Martin P.R. Longitudinal brain metabolic characterization of chronic alcoholics with proton magnetic resonance spectroscopy. Alcohol Clin. Exp. Res. 26 (2002) 1368-1380
290. Parsons M.W., Li T., Barber P.A., Yang Q., Darby D.G., Desmond P.M., Gerraty R.P., Tress B.M., and Davis S.M. Combined (1)H MR spectroscopy and diffusion-weighted MRI improves the prediction of stroke outcome. Neurology 55 (2000) 498-505
291. Passani L., Elkabes S., and Coyle J.T. Evidence for the presence of N-acetylaspartylglutamate in cultured oligodendrocytes and LPS activated microglia. Brain Res. 794 (1998) 143-145
292. Patel T.B., and Clark J.B. Synthesis of N-acetyl-l-aspartate by rat brain mitochondria and its involvement in mitochondrial/cytosolic carbon transport. Biochem. J. 184 (1979) 539-546
293. Patel T.B., and Clark J.B. Mitochondrial/cytosolic carbon transfer in the developing rat brain. Biochim. Biophys. Acta 677 (1981) 373-380
294. Petroff O.A., Ogino T., and Alger J.R. High-resolution proton magnetic resonance spectroscopy of rabbit brain: regional metabolite levels postmortem changes. Neurochem. J. 51 (1988) 163-171
295. Pizzini F., Fatemi A.S., Barker P.B., Nagae-Poetscher L.M., Horska A., Zimmerman A.W., Moser H.W., Bibat G., and Naidu S. Proton MR spectroscopic imaging in Pelizaeus-Merzbacher disease. AJNR Am. J. Neuroradiol. 24 (2003) 1683-1689
296. Pleasure D., Lichtman C., Eastman S., Lieb M., Abramsky O., and Silberberg D. Acetoacetate and d-(-)-beta-hydroxybutyrate as precursors for sterol synthesis by calf oligodendrocytes in suspension culture: extramitochondrial pathway for acetoacetate metabolism. J. Neurochem. 32 (1979) 1447-1450
297. Pliss L., Balcar V.J., Bubenikova V., Pokorny J., FitzGibbon T., and St'astny F. Morphology and ultrastructure of rat hippocampal formation after i.c.v. administration of N-acetyl-l-aspartyl-l-glutamate. Neuroscience 122 (2003) 93-101
298. Popko B. Myelin galactolipids: mediators of axon-glial interactions?. Glia 29 (2000) 149-153
299. Port R.E., and Wolf W. Noninvasive methods to study drug distribution. Invest. New Drugs 21 (2003) 157-168
300. Pouwels P.J., and Frahm J. Differential distribution of NAA and NAAG in human brain as determined by quantitative localized proton MRS. NMR Biomed. 10 (1997) 73-78
301. Pouwels P.J., and Frahm J. Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS. Magn. Reson. Med. 39 (1998) 53-60
302. Pratt H. Canavan's disease and spongiform encephalopathy. Br. Med. J. 4 (1972) 427
303. Raichle M.E., MacLeod A.M., Snyder A.Z., Powers W.J., Gusnard D.A., and Shulman G.L. A default mode of brain function. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 676-682
304. Ramos M., Del Arco A., Pardo B., Martinez-Serrano A., Martinez-Morales J.R., Kobayashi K., Yasuda T., Bogonez E., Bovolenta P., Saheki T., and Satrustegui J. Developmental changes in the Ca2+-regulated mitochondrial aspartate-glutamate carrier aralar1 in brain and prominent expression in the spinal cord. Brain Res. Dev. Brain Res. 143 (2003) 33-46
305. Reichelt K.L., Edminson P.D., and Kvamme E. The formation of peptido-amines from constituent amino acids and histamine in hypothalamic tissue. J. Neurochem. 26 (1976) 811-815
306. Reichelt K.L., and Kvamme E. Histamine-dependent formation of N-acetyl-aspartyl peptides in mouse brain. J. Neurochem. 21 (1973) 849-859
307. Ricciolini R., Scalibastri M., Kelleher J.K., Carminati P., Calvani M., and Arduini A. Role of acetyl-l-carnitine in rat brain lipogenesis: implications for polyunsaturated fatty acid biosynthesis. J. Neurochem. 71 (1998) 2510-2517
308. Rooney W.D., Miller R.G., Gelinas D., Schuff N., Maudsley A.A., and Weiner M.W. Decreased N-acetylaspartate in motor cortex and corticospinal tract in ALS. Neurology 50 (1998) 1800-1805
309. Ross B.D., Ernst T., Kreis R., Haseler L.J., Bayer S., Danielsen E., Bluml S., Shonk T., Mandigo J.C., Caton W., Clark C., Jensen S.W., Lehman N.L., Arcinue E., Pudenz R., and Shelden C.H. 1H MRS in acute traumatic brain injury. J. Magn. Reson. Imaging 8 (1998) 829-840
310. Rowland L., Bustillo J.R., and Lauriello J. Proton magnetic resonance spectroscopy (H-MRS) studies of schizophrenia. Semin. Clin. Neuropsychiatry 6 (2001) 121-130
311. Sager T.N., Hansen A.J., and Laursen H. Correlation between N-acetylaspartate levels and histopathologic changes in cortical infarcts of mice after middle cerebral artery occlusion. J. Cereb. Blood Flow Metab. 20 (2000) 780-788
312. Sager T.N., Laursen H., Fink-Jensen A., Topp S., Stensgaard A., Hedehus M., Rosenbaum S., Valsborg J.S., and Hansen A.J. N-Acetylaspartate distribution in rat brain striatum during acute brain ischemia. J. Cereb. Blood Flow Metab. 19 (1999) 164-172
313. Sager T.N., Laursen H., and Hansen A.J. Changes in N-acetyl-aspartate content during focal and global brain ischemia of the rat. J. Cereb. Blood Flow Metab. 15 (1995) 639-646
314. Sager T.N., Thomsen C., Valsborg J.S., Laursen H., and Hansen A.J. Astroglia contain a specific transport mechanism for N-acetyl-l-aspartate. J. Neurochem. 73 (1999) 807-811
315. Sager T.N., Topp S., Torup L., Hanson L.G., Egestad B., and Moller A. Evaluation of CA1 damage using single-voxel 1H-MRS and un-biased stereology: can non-invasive measures of N-acetyl-asparate following global ischemia be used as a reliable measure of neuronal damage?. Brain Res. 892 (2001) 166-175
316. Schousboe A., Westergaard N., Waagepetersen H.S., Larsson O.M., Bakken I.J., and Sonnewald U. Trafficking between glia and neurons of TCA cycle intermediates and related metabolites. Glia 21 (1997) 99-105
317. Schuff N., Capizzano A.A., Du A.T., Amend D.L., O'Neill J., Norman D., Kramer J., Jagust W., Miller B., Wolkowitz O.M., Yaffe K., and Weiner M.W. Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD. Neurology 58 (2002) 928-935
318. Schuff N., Meyerhoff D.J., Mueller S., Chao L., Sacrey D.T., Laxer K., and Weiner M.W. N-acetylaspartate as a marker of neuronal injury in neurodegenerative disease. In: Moffett J.R., Tieman S.B., Weinberger D.R., Coyle J.T., and Namboodiri M.A. (Eds). N-Acetylaspartate: A Unique Neuronal Molecule in the Central Nervous System (2006), Springer Science, New York, NY 241-262
319. Seki T., Matsubayashi H., Amano T., Kitada K., Serikawa T., Sakai N., and Sasa M. Adenoviral gene transfer of aspartoacylase into the tremor rat, a genetic model of epilepsy, as a trial of gene therapy for inherited epileptic disorder. Neurosci. Lett. 328 (2002) 249-252
320. Seki T., Matsubayashi H., Amano T., Kitada K., Serikawa T., Sasa M., and Sakai N. Adenoviral gene transfer of aspartoacylase ameliorates tonic convulsions of spontaneously epileptic rats. Neurochem. Int. 45 (2004) 171-178
321. Selemon L.D., and Goldman-Rakic P.S. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol. Psychiatry 45 (1999) 17-25
322. Selemon L.D., Kleinman J.E., Herman M.M., and Goldman-Rakic P.S. Smaller frontal gray matter volume in postmortem schizophrenic brains. Am. J. Psychiatry 159 (2002) 1983-1991
323. Serikawa T., Ohno Y., Sasa M., Yamada J., and Takaori S. A new model of petit mal epilepsy: spontaneous spike and wave discharges in tremor rats. Lab. Anim. 21 (1987) 68-71
324. Serles W., Li L.M., Antel S.B., Cendes F., Gotman J., Olivier A., Andermann F., Dubeau F., and Arnold D.L. Time course of postoperative recovery of N-acetyl-aspartate in temporal lobe epilepsy. Epilepsia 42 (2001) 190-197
325. Shenton M.E., Dickey C.C., Frumin M., and McCarley R.W. A review of MRI findings in schizophrenia. Schizophr. Res. 49 (2001) 1-52
326. Shigematsu H., Okamura N., Shimeno H., Kishimoto Y., Kan L., and Fenselau C. Purification and characterization of the heat-stable factors essential for the conversion of lignoceric acid to cerebronic acid and glutamic acid: identification of N-acetyl-l-aspartic acid. J. Neurochem. 40 (1983) 814-820
327. Shonk T.K., Moats R.A., Gifford P., Michaelis T., Mandigo J.C., Izumi J., and Ross B.D. Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology 195 (1995) 65-72
328. Signoretti S., Marmarou A., Tavazzi B., Dunbar J., Amorini A.M., Lazzarino G., and Vagnozzi R. The protective effect of cyclosporin A upon N-acetylaspartate and mitochondrial dysfunction following experimental diffuse traumatic brain injury. J. Neurotrauma 21 (2004) 1154-1167
329. Signoretti S., Marmarou A., Tavazzi B., Lazzarino G., Beaumont A., and Vagnozzi R. N-Acetylaspartate reduction as a measure of injury severity and mitochondrial dysfunction following diffuse traumatic brain injury. J. Neurotrauma 18 (2001) 977-991
330. Simmons M.L., Frondoza C.G., and Coyle J.T. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 45 (1991) 37-45
331. Simons M., Kramer E.M., Macchi P., Rathke-Hartlieb S., Trotter J., Nave K.A., and Schulz J.B. Overexpression of the myelin proteolipid protein leads to accumulation of cholesterol and proteolipid protein in endosomes/lysosomes: implications for Pelizaeus-Merzbacher disease. J. Cell Biol. 157 (2002) 327-336
332. Sinichkin A., Sterri S., Edminson P.D., Reichelt K.L., and Kvamme E. In vivo labelling of acetyl-aspartyl peptides in mouse brain from intracranially and intraperitoneally administered acetyl-l-[U-14C]aspartate. J. Neurochem. 29 (1977) 425-431
333. Sistermans E.A., de Coo R.F., van Beerendonk H.M., Poll-The B.T., Kleijer W.J., and van Oost B.A. Mutation detection in the aspartoacylase gene in 17 patients with Canavan disease: four new mutations in the non-Jewish population. Eur. J. Hum. Genet. 8 (2000) 557-560
334. Slusher B.S., Tsai G., Yoo G., and Coyle J.T. Immunocytochemical localization of the N-acetyl-aspartyl-glutamate (NAAG) hydrolyzing enzyme N-acetylated alpha-linked acidic dipeptidase (NAALADase). J. Comp. Neurol. 315 (1992) 217-229
335. Staffen W., Zauner H., Mair A., Kutzelnigg A., Kapeller P., Stangl H., Raffer E., Niederhofer H., and Ladurner G. Magnetic resonance spectroscopy of memory and frontal brain region in early multiple sclerosis. J. Neuropsychiatry Clin. Neurosci. 17 (2005) 357-363
336. Stanley J.A., Pettegrew J.W., and Keshavan M.S. Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings-part I. Biol. Psychiatry 48 (2000) 357-368
337. Steen R.G., Hamer R.M., and Lieberman J.A. Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology 30 (2005) 1949-1962
338. Steen R.G., and Ogg R.J. Abnormally high levels of brain N-acetylaspartate in children with sickle cell disease. AJNR Am. J. Neuroradiol. 26 (2005) 463-468
339. Tabernero A., Vicario C., and Medina J.M. Lactate spares glucose as a metabolic fuel in neurons and astrocytes from primary culture. Neurosci. Res. 26 (1996) 369-376
340. Takanashi J., Inoue K., Tomita M., Kurihara A., Morita F., Ikehira H., Tanada S., Yoshitome E., and Kohno Y. Brain N-acetylaspartate is elevated in Pelizaeus-Merzbacher disease with PLP1 duplication. Neurology 58 (2002) 237-241
341. Tallan H.H. Studies on the distribution of N-acetyl-l-aspartic acid in brain. J. Biol. Chem. 224 (1957) 41-45
342. Tallan H.H., Moore S., and Stein W.H. N-Acetyl-l-aspartic acid in brain. J. Biol. Chem. 219 (1956) 257-264
343. Tanaka Y., Obata T., Sassa T., Yoshitome E., Asai Y., Ikehira H., Suhara T., Okubo Y., and Nishikawa T. Quantitative magnetic resonance spectroscopy of schizophrenia: relationship between decreased N-acetylaspartate and frontal lobe dysfunction. Psychiatry Clin. Neurosci. 60 (2006) 365-372
344. Tavazzi B., Signoretti S., Lazzarino G., Amorini A.M., Delfini R., Cimatti M., Marmarou A., and Vagnozzi R. Cerebral oxidative stress and depression of energy metabolism correlate with severity of diffuse brain injury in rats. Neurosurgery 56 (2005) 582-589
345. Taylor D.L., Davies S.E., Obrenovitch T.P., Doheny M.H., Patsalos P.N., Clark J.B., and Symon L. Investigation into the role of N-acetylaspartate in cerebral osmoregulation. J. Neurochem. 65 (1995) 275-281
346. Taylor D.L., Davies S.E., Obrenovitch T.P., Urenjak J., Richards D.A., Clark J.B., and Symon L. Extracellular N-acetylaspartate in the rat brain: in vivo determination of basal levels and changes evoked by high K+. J. Neurochem. 62 (1994) 2349-2355
347. Tedeschi G., Bonavita S., McFarland H.F., Richert N., Duyn J.H., and Frank J.A. Proton MR spectroscopic imaging in multiple sclerosis. Neuroradiology 44 (2002) 37-42
348. Thatcher N.M., Badar-Goffer R.S., Ben-Yoseph O., McLean M.A., Morris P.G., Prior M.J., Taylor A., and Bachelard H.S. A comparison of some metabolic effects of N-methylaspartate stereoisomers, glutamate and depolarization: a multinuclear MRS study. Neurochem. Res. 27 (2002) 51-58
349. Tieman S.B., Neale J.H., and Tieman D.G. N-acetylaspartylglutamate immunoreactivity in neurons of the monkey's visual pathway. J. Comp. Neurol. 313 (1991) 45-64
350. Tieman S.B., and Tieman D.G. N-acetylaspartylglutamate immunoreactivity in human retina. Vision Res. 36 (1996) 941-947
351. Tranberg M., Stridh M.H., Guy Y., Jilderos B., Wigstrom H., Weber S.G., and Sandberg M. NMDA-receptor mediated efflux of N-acetylaspartate: physiological and/or pathological importance?. Neurochem. Int. 45 (2004) 1195-1204
352. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mork S., and Bo L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338 (1998) 278-285
353. Truckenmiller M.E., Namboodiri M.A., Brownstein M.J., and Neale J.H. N-Acetylation of l-aspartate in the nervous system: differential distribution of a specific enzyme. J. Neurochem. 45 (1985) 1658-1662
354. Tsai G., and Coyle J.T. N-acetylaspartate in neuropsychiatric disorders. Prog. Neurobiol. 46 (1995) 531-540
355. Tsai G., Passani L.A., Slusher B.S., Carter R., Baer L., Kleinman J.E., and Coyle J.T. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch. Gen. Psychiatry 52 (1995) 829-836
356. Tsai G., van Kammen D.P., Chen S., Kelley M.E., Grier A., and Coyle J.T. Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia. Biol. Psychiatry 44 (1998) 667-674
357. Tyson R.L., Gallagher C., and Sutherland G.R. 13C-Labeled substrates and the cerebral metabolic compartmentalization of acetate and lactate. Brain Res. 992 (2003) 43-52
358. Tyson R.L., and Sutherland G.R. Labeling of N-acetylaspartate and N-acetylaspartylglutamate in rat neocortex, hippocampus and cerebellum from [1-13C]glucose. Neurosci. Lett. 251 (1998) 181-184
359. Urazaev A.K., Grossfeld R.M., Fletcher P.L., Speno H., Gafurov B.S., Buttram J.G., and Lieberman E.M. Synthesis and release of N-acetylaspartylglutamate (NAAG) by crayfish nerve fibers: implications for axon-glia signaling. Neuroscience 106 (2001) 237-247
360. Urenjak J., Williams S.R., Gadian D.G., and Noble M. Specific expression of N-acetylaspartate in neurons, oligodendrocyte-type-2 astrocyte progenitors, and immature oligodendrocytes in vitro. J. Neurochem. 59 (1992) 55-61
361. Vagnozzi R., Signoretti S., Tavazzi B., Cimatti M., Amorini A.M., Donzelli S., Delfini R., and Lazzarino G. Hypothesis of the postconcussive vulnerable brain: experimental evidence of its metabolic occurrence. Neurosurgery 57 (2005) 164-171
362. van Bogaert L., and Bertrand I. Sur une idiotie familiale avec degerescence sponglieuse de neuraxe (note preliminaire). Acta Neurol. 49 (1949) 572-587
363. van Haren N.E., Cahn W., Hulshoff Pol H.E., Schnack H.G., Caspers E., Lemstra A., Sitskoorn M.M., Wiersma D., van den Bosch R.J., Dingemans P.M., Schene A.H., and Kahn R.S. Brain volumes as predictor of outcome in recent-onset schizophrenia: a multi-center MRI study. Schizophr. Res. 64 (2003) 41-52
364. Varho T., Komu M., Sonninen P., Holopainen I., Nyman S., Manner T., Sillanpaa M., Aula P., and Lundbom N. A new metabolite contributing to N-acetyl signal in 1H MRS of the brain in Salla disease. Neurology 52 (1999) 1668-1672
365. Verbalis J.G. Control of brain volume during hypoosmolality and hyperosmolality. In: Moffett J.R., Tieman S.B., Weinberger D.R., Coyle J.T., and Namboodiri M.A. (Eds). N-Acetylaspartate: A Unique Neuronal Molecule in the Central Nervous System (2006), Springer Science, New York, NY 113-129
366. Vermathen P., Ende G., Laxer K.D., Walker J.A., Knowlton R.C., Barbaro N.M., Matson G.B., and Weiner M.W. Temporal lobectomy for epilepsy: recovery of the contralateral hippocampus measured by (1)H MRS. Neurology 59 (2002) 633-636
367. Vion-Dury J., Confort-Gouny S., Nicoli F., Dhiver C., Gastaut J.A., Gastaut J.L., and Cozzone P.J. Localized brain proton MRS metabolic patterns in HIV-related encephalopathies. C. R. Acad. Sci. III 317 (1994) 833-840
368. Waldman A.D., Rai G.S., McConnell J.R., Chaudry M., and Grant D. Clinical brain proton magnetic resonance spectroscopy for management of Alzheimer's and sub-cortical ischemic vascular dementia in older people. Arch. Gerontol. Geriatr. 35 (2002) 137-142
369. Walker P.M., Ben S.D., Giroud M., and Brunotte F. Is NAA reduction in normal contralateral cerebral tissue in stroke patients dependent on underlying risk factors?. J. Neurol. Neurosurg. Psychiatry 77 (2006) 596-600
370. Walker P.M., Ben S.D., Lalande A., Giroud M., and Brunotte F. Time course of NAA T2 and ADC(w) in ischaemic stroke patients: 1H MRS imaging and diffusion-weighted MRI. J. Neurol. Sci. 220 (2004) 23-28
371. Wang X., Qian J., He R., Wei L., Liu N., Zhang Z., Huang Y., and Lei H. Delayed changes in T1-weighted signal intensity in a rat model of 15-min transient focal ischemia studied by magnetic resonance imaging/spectroscopy and synchrotron radiation X-ray fluorescence. Magn. Reson. Med. 56 (2006) 474-480
372. Waniewski R.A., and Martin D.L. Preferential utilization of acetate by astrocytes is attributable to transport. J. Neurosci. 18 (1998) 5225-5233
373. Wild J.M., Wardlaw J.M., Marshall I., and Warlow C.P. N-acetylaspartate distribution in proton spectroscopic images of ischemic stroke: relationship to infarct appearance on T2-weighted magnetic resonance imaging. Stroke 31 (2000) 3008-3014
374. Williamson L.C., Eagles D.A., Brady M.J., Moffett J.R., Namboodiri M.A., and Neale J.H. Localization and synaptic release of N-acetylaspartylglutamate in the chick retina and optic tectum. Eur. J. Neurosci. 3 (1991) 441-451
375. Williamson L.C., and Neale J.H. Calcium-dependent release of N-acetylaspartylglutamate from retinal neurons upon depolarization. Brain Res. 475 (1988) 151-155
376. Williamson L.C., and Neale J.H. Uptake, metabolism, and release of N-[3H]acetylaspartylglutamate by the avian retina. J. Neurochem. 58 (1992) 2191-2199
377. Wittsack H.J., Kugel H., Roth B., and Heindel W. Quantitative measurements with localized 1H MR spectroscopy in children with Canavan's disease. J. Magn. Reson. Imaging 6 (1996) 889-893
378. Wolf N.I., Sistermans E.A., Cundall M., Hobson G.M., vis-Williams A.P., Palmer R., Stubbs P., Davies S., Endziniene M., Wu Y., Chong W.K., Malcolm S., Surtees R., Garbern J.Y., and Woodward K.J. Three or more copies of the proteolipid protein gene PLP1 cause severe Pelizaeus-Merzbacher disease. Brain 128 (2005) 743-751
379. Wolf N.I., Willemsen M.A., Engelke U.F., van der Knaap M.S., Pouwels P.J., Harting I., Zschocke J., Sistermans E.A., Rating D., and Wevers R.A. Severe hypomyelination associated with increased levels of N-acetylaspartylglutamate in CSF. Neurology 62 (2004) 1503-1508
380. Wolfe A.J. The acetate switch. Microbiol. Mol. Biol. Rev. 69 (2005) 12-50
381. Wolinsky J.S., and Narayana P.A. Magnetic resonance spectroscopy in multiple sclerosis: window into the diseased brain. Curr. Opin. Neurol. 15 (2002) 247-251
382. Wood S.J., Berger G.E., Lambert M., Conus P., Velakoulis D., Stuart G.W., Desmond P., McGorry P.D., and Pantelis C. Prediction of functional outcome 18 months after a first psychotic episode: a proton magnetic resonance spectroscopy study. Arch. Gen. Psychiatry 63 (2006) 969-976
383. Xi Z.X., Baker D.A., Shen H., Carson D.S., and Kalivas P.W. Group II metabotropic glutamate receptors modulate extracellular glutamate in the nucleus accumbens. J. Pharmacol. Exp. Ther. 300 (2002) 162-171
384. Yan H.D., Ishihara K., Serikawa T., and Sasa M. Activation by N-Acetyl-l-aspartate of acutely dissociated hippocampal neurons in rats via metabotropic glutamate receptors. Epilepsia 44 (2003) 1153-1159
385. Yaron Y., Schwartz T., Mey-Raz N., Amit A., Lessing J.B., and Malcov M. Preimplantation genetic diagnosis of Canavan disease. Fetal Diagn. Ther. 20 (2005) 465-468
386. Yeo R.A., Brooks W.M., and Jung R.E. NAA and higher cognitive function in humans. In: Moffett J.R., Tieman S.B., Weinberger D.R., Coyle J.T., and Namboodiri M.A. (Eds). N-Acetylaspartate: A Unique Neuronal Molecule in the Central Nervous System (2006), Springer Science, New York, NY 215-226
387. Yi L., Zhang S., and Zhang X. An experimental proton magnetic resonance spectroscopy analysis on early stage of acute focal cerebral ischemia. J. Huazhong. Univ. Sci. Technol. Med. Sci. 22 (2002) 359-361 366
388. Yudkoff M., Nelson D., Daikhin Y., and Erecinska M. Tricarboxylic acid cycle in rat brain synaptosomes. Fluxes and interactions with aspartate aminotransferase and malate/aspartate shuttle. J. Biol. Chem. 269 (1994) 27414-27420
389. Zambell K.L., Fitch M.D., and Fleming S.E. Acetate and butyrate are the major substrates for de novo lipogenesis in rat colonic epithelial cells. J. Nutr. 133 (2003) 3509-3515
390. Zeng B.J., Wang Z.H., Ribeiro L.A., Leone P., De Gasperi R., Kim S.J., Raghavan S., Ong E., Pastores G.M., and Kolodny E.H. Identification and characterization of novel mutations of the aspartoacylase gene in non-Jewish patients with Canavan disease. J. Inherit. Metab. Dis. 25 (2002) 557-570
391. Zhao J., Ramadan E., Cappiello M., Wroblewska B., Bzdega T., and Neale J.H. NAAG inhibits KCl-induced [(3)H]-GABA release via mGluR3, camp, PKA and l-type calcium conductance. Eur. J. Neurosci. 13 (2001) 340-346